DV2-HBV-27: Observational Pregnancy Registry

Dynavax Technologies Corporation

Status: Active, not recruiting

Conditions: Pregnant

Treatments: Biological: HEPLISAV-B

Study type: Observational

Funder types: Industry

Identifiers

NCT03664648

DV2-HBV-27

Details and patient eligibility

About

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy

Enrollment: 300 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 years and older
• HEPLISAV-B exposure within 28 days prior to conception or at any time during pregnancy

Exclusion criteria

• Less than 18 years of age
• HEPLISAV-B exposure greater than 28 days prior to conception

Trial design

300 participants in 1 patient group

Adult Pregnant Women Exposed to HEPLISAV-B

Description:

Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.

Treatment:

Biological: HEPLISAV-B